Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01436149 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
A Phase 3 study, sponsored by Shire.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,262
- Enrollment target
NCT01436149 is a Phase 3 study that has completed, run by Shire. The registered enrollment target is 1,262 participants.
The verdict
NCT01436149, a Phase 3 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,262 participants
- Enrollment target
Study Summary
This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms. Eligible patients will remain on their antidepressant but will be randomized to either receive supplemental SPD489 or placebo (i.e. sugar pill). The purpose of this study is to help answer the following questions: * How safe is SPD489 for the supplemental treatment of depression and what are the side effects that might be related to it? * Can supplemental SPD489 help patients who still have residual depression symptoms while taking an antidepressant? * How much SPD489 should be given to patients with depression who are also taking an antidepressant? * How does SPD489 compare to placebo in depressed patients who are also taking an antidepressant?
Interventions
- DRUG Placebo
- DRUG SPD489 (Lisdexamfetamine dimesylate )
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,262 participants |
| Start Date | 2011-10-27 |
| Est. Completion | 2013-12-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01436149
The ClinicalTrials.gov registry entry for NCT01436149 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,262 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01436149 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01436149 about?
NCT01436149 is a clinical study titled "Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder". This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms. Eligible patients will remain on their antidepressant but will be randomized to either receive supplemental SP...
What is the current status of trial NCT01436149?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,262 participants. The study started on 2011-10-27. Estimated completion is 2013-12-23.
What interventions are being tested in trial NCT01436149?
The interventions under investigation include: Placebo (DRUG), SPD489 (Lisdexamfetamine dimesylate ) (DRUG).
Who is sponsoring clinical trial NCT01436149?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.